Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Inequality in access to CAR-T therapy in multiple myeloma and the importance of addressing this

Larry Anderson • 28 Sep 2023
IMS 2023
Multiple Myeloma CAR-T

Larry Anderson, MD, PhD, UT Southwestern Medical Center, Dallas, TX, briefly discusses the problem of inequality in access to CAR-T therapy in multiple myeloma, which has been suboptimal due to limited slot availability, and further comments on the need to improve access if these agents are moved into earlier lines of therapy. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Advisory/consultant to BMS, Janssen, Celgene, AbbVie, GSK

More from Larry Anderson

2:58
The impact of bridging therapy on the outcomes of patients with R/R myeloma treated with ide-cel
Larry Anderson • 28 Sep 2023
5:16
Updated KarMMa results: ide-cel in R/R myeloma
Larry Anderson • 4 Jun 2021
0:59
Further improvements of ide-cel therapy in KarMMa trials
Larry Anderson • 4 Jun 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals